EVENT May 15, 2018

2018 Pre-IID Pemphigus and Pemphigoid Symposium

Updated results from the BP-01 phase 2a study of bertilimumab in bullous pemphigoid are being presented at the pre-IID Pemphigus and Pemphigoid Symposium in Orlando, Florida on May 15.  The data will be featured in an oral presentation by Neil Korman, MD, PhD, Director Clinical Trials Unit and the Murdough Family Center for Psoriasis, University Hospitals […]

Keep Reading

EVENT January 23, 2018

NobleCon 14 Annual Investor Conference

Date:  Tuesday, January 30, 2018 Time:  2:30 P.M. EST Room:  Studio 1 Location:  W Fort Lauderdale, 401 N Fort Lauderdale Beach Blvd, Fort Lauderdale, FL 33304 Webcast:  http://noble.mediasite.com/mediasite/Play/187d50750006440a800ea4e8bcf113e11d 

Keep Reading

EVENT January 4, 2018

Biotech Showcase™ Annual Conference

Date:  Wednesday, January 10, 2018 Time: 9:30 A.M. PST Room: Yosemite – A (Ballroom Level) Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (USA) Webcast: https://event.webcasts.com/starthere.jsp?ei=1176714&tp_key=ab81c8f855  

Keep Reading

EVENT March 11, 2017

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL.

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in Bullous Pemphigoid were presented last Saturday at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL. Pr. Neil Korman, MD, PhD, FAAD spoke on March, 4th 2017 at the F076 – AUTOIMMUNE BLISTERING DISEASES: WHAT’S NEW scientific session, directed by Pr. […]

Keep Reading

EVENT February 24, 2017

IMNP Dermatology (Bullous Pemphigoid and Atopic Dermatitis) Educational Symposium

The following subjects in dermatology will be presented and discussed: The Need for New Therapies to Treat Bullous Pemphigoid and Atopic Dermatitis – Neil J. Korman, MD, PhD, Case Western, Cleveland, OH Rationale for Using Bertilimumab in a Bullous Pemphigoid Trial – Animesh A. Sinha, MD, PhD, University at Buffalo, NY Novel Pathogenic Developments in Atopic Dermatitis and Implications for […]

Keep Reading

EVENT February 22, 2017

IMNP Symposium at ACUTE LEUKEMIAS XVI, Munich, Feb 2017

Biology and Treatment Strategies Munich, Germany – February 19-22, 2017 Immune Pharmaceuticals Symposium Professor Kristoffer Hellstrand (University of Gothenburg) Presents the Role of Cytotoxic T-Cells in Remission Maintenance with Ceplene/Proleukin Therapy in AML      Professor Jacob Rowe (Shaare Zedek, Jeruslaem) Describes the Potential of Ceplene/Proleukin, the Only Clinically Proven Maintenance Therapy in AML

Keep Reading

EVENT January 27, 2017

Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI

Immune will hold a Satellite Symposium on February 20th, 2017 at the International Symposium on Acute Leukemias (ISAL) XVI in Munich, Germany. The satellite symposium is entitled: “Reinforcing the Efficacy of Immunotherapy for the maintenance of remission in AML with Ceplene” and will take place on Monday February 20th, 2017 from 12:45 – 13:45 CET in Lecture Hall III/IV in […]

Keep Reading

EVENT January 4, 2017

R&D Trends: What’s Changed in the Pharma Pipeline?

Panel discussion at the East/West CEO Conference, San Francisco, January 8th, 3:00-3:30 pm Susan Herbert, EVP, Global Head, Marketing & Strategy, EMD Serono; Tom Heyman, President, Johnson & Johnson Innovation, JJDC; Vivek Ramaswamy, CEO, Roivant Sciences and Axovant Sciences; Daniel Teper, CEO, Immune Pharmaceuticals Moderator: Joel Marcus, CEO, Alexandria Ventures Read more details about the conference here.

Keep Reading